The use of monoclonal antibodies (mAbs) to target the PD-1/PD-L1 immune signaling pathway has proven to be a highly successful immunotherapy for a range of cancers, with three approved mAbs targeting PD-L1 in clinical use and several currently under development (1). The gene discussed is CD274; the disease is cancer.